Introduction The markets segments for therapeutics for hematological malignancies are numerous and complicated. The historical general conception that relatively low prevalence diseases, has been insufficient in size to allow companies to quickly regain their investment is clearly out of date. In this perspective enhanced development is expected. Among the emerging therapeutic strategies, passive and active immunotherapies have clearly continued to be leading strategies. Small molecule apoptotic inducers and kinase inhibitors are as well in the forefront. About this report In this unique report, Global Pipeline Review & Analysis of Hematological Malignancies, BioSeeker reports on the hematological cancer pipeline by: - Investigator - Includes 212 investigators and partners
- Drug - Includes 237 "active" drugs
- Sub-indication - Includes 11 sub-indications
- Developmental stage - Includes 8 developmental stages
- Compound type - Includes 21 different compounds types
- Targeted therapy strategy - Includes 5 different targeted therapy strategies
- Target - Includes 97 different protein targets
- Signaling pathway - Includes 18 different signaling pathways
All of above "factors" are cross referenced against each other, generating highly valuable insights in 40 figures and 53 tables. Read more below about each "factor" included in this cutting edge analysis. Investigator This report includes 212 investigators and partners from all over the world. Drug There are today more than 237 therapeutics for the treatment of hematological cancers, from early preclinical to marketed drugs. Each drug is annotated with a brief drug description. Sub-indication The hematological cancer drug pipeline is broken down into 11 sub-indications: - Cancer, leukemia, acute lymphocytic
- Cancer, leukemia, acute myelogenous
- Cancer, leukemia, chronic lymphocytic
- Cancer, leukemia, chronic myelogenous
- Cancer, leukemia, general
- Cancer, leukemia, hairy cell
| - Cancer, lymphoma, B-cell
- Cancer, lymphoma, general
- Cancer, lymphoma, Hodgkin`s
- Cancer, lymphoma, non-Hodgkin`s
- Cancer, lymphoma, T-cell
|
Only the highest developmental stage per drug and indication is accounted for. Developmental Stage Each sub-indication of a drug is described with its developmental stage: - Preclinical
- Clinical Trial
- Phase I Clinical Trial
- Phase II Clinical Trial
| - Phase III Clinical Trial
- Pre-registration
- Registered
- Marketed
|
Compound Type BioSeeker has described all 237 drugs in the hematological malignancies pipeline with its corresponding compound type: - Biological
- Biological, bacterial cells
- Biological, cellular, autologous
- Biological, cellular, heterologous
- Biological, nucleic acid
- Biological, nucleic acid, non-viral vector
- Biological, nucleic acid, viral vector
- Biological, peptide
- Biological, peptide, recombinant
- Biological, protein
- Biological, protein, antibody
| - Biological, protein, recombinant
- Chemical, semisynthetic
- Chemical, synthetic
- Chemical, synthetic, isomeric
- Chemical, synthetic, nucleic acid
- Chemical, synthetic, peptide
- Natural product
- Natural product, animal
- Natural product, bacterial
- Natural product, plant
|
When available, drug compounds are further described with chemical name, CAS number, chemical formula and molecular weight. Targeted Therapy Strategy This report categorizes available drugs into 5 major targeted therapy strategies:
1.Angiogenesis
2. Antibody
3. Apoptosis
4. Protein Kinase Inhibitors
5. Vaccines Target This analysis includes 97 protein targets, linked to 165 drugs for the treatment of hematological cancers. All protein targets are described by its primary localization, molecular class, molecular function, and biological process: Primary Localization of Target: - Cell surface
- Centrosome
- Cytoplasm
- Cytosol
- Endoplasmic reticulum
- Extracellular
- Integral to membrane
| - Lysosome
- Mitochondrial membrane
- Mitochondrion
- Nucleus
- Plasma membrane
- Secretory granule
|
Molecular Class of Target: - Adapter molecule
- Adhesion molecule
- Cell cycle control protein
- Cell surface receptor
- Chaperone
- Cysteine protease
- Cytokine
- Cytokine receptor
- Cytoskeletal protein
- DNA methyltransferase
- DNA polymerase
- DNA repair protein
- Enzyme: Deaminase
- Enzyme: Decarboxylase
- Enzyme: Hydrolase
- Enzyme: Ligase
- Enzyme: Oxidoreductase
- Enzyme: Phosphorylase
- Enzyme: Topoisomerase
| - Enzyme: Transferase
- G protein coupled receptor
- Growth factor
- Integral membrane protein
- Ligand
- Lipid phosphatase
- Membrane bound ligand
- MHC complex protein
- Nuclear receptor
- Receptor tyrosine kinase
- Serine protease
- Serine/threonine kinase
- T cell antigen receptor
- Transcription factor
- Transcription regulatory protein
- Translation regulatory protein
- Transport/cargo protein
- Tyrosine kinase
- Unclassified
|
Molecular Function of Target: - Carboxy-lyase activity
- Cell adhesion molecule activity
- Chaperone activity
- Cysteine-type peptidase activity
- Cytokine activity
- Deaminase activity
- DNA repair protein
- DNA topoisomerase activity
- DNA-directed DNA polymerase activity
- DNA-methyltransferase activity
- G-protein coupled receptor activity
- Growth factor activity
- Hydrolase activity
- Kinase activity
- Ligand-dependent nuclear receptor activity
- Ligase activity
- Lipid phosphatase activity
- MHC class I receptor activity
- Molecular function unknown
- Oxidoreductase activity
| - Phosphorylase activity
- Protein binding
- Protein serine/threonine kinase activity
- Protein-tyrosine kinase activity
- Receptor activity
- Receptor binding
- Receptor signaling complex scaffold activity
- Serine-type peptidase activity
- Structural constituent of cytoskeleton
- T cell receptor activity
- Transcription factor activity
- Transcription regulator activity
- Transferase activity
- Translation regulator activity
- Transmembrane receptor activity
- Transmembrane receptor protein tyrosine kinase activity
- Transporter activity
- Unclassified
|
Biological Process of Target: - Anti-apoptosis
- Apoptosis
- Cell communication
- Cell communication ; Cell surface receptor linked signal transduction
- Cell communication ; Signal transduction
- Cell communication ; Signal transduction ; Transport
- Cell growth and/or maintenance
- Enzyme linked receptor protein signaling pathway ; Cellular morphogenesis during differentiation
| - Immune response
- Metabolism
- Metabolism ; Energy pathways
- Protein metabolism
- Protein modification
- Regulation of cell cycle
- Regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism
- Signal transduction
- Transport
|
Signaling Pathway The 97 available protein targets have been compared with molecular entities in known signaling pathways. This analysis showed the involvement of hematological drugs in at least 18 different signaling pathways: - Alpha6 Beta4 Integrin Signaling Pathway
- Androgen Receptor Signaling Pathway
- B Cell Receptor Signaling Pathway
- EGFR1 Signaling Pathway
- ID Signaling Pathway
- IL-1 Singaling Pathway
- IL-2 Signaling Pathway
- IL-3 Signaling Pathway
- IL-4 Signaling Pathway
| - IL-5 Signaling Pathway
- IL-6 Signaling Pathway
- IL-7 Signaling Pathway
- Kit Receptor Signaling Pathway
- Notch Signaling Pathway
- T Cell Receptor Signaling Pathway
- TGF-beta Receptor Signaling Pathway
- TNF-alpha Signaling Pathway
- Wnt Signaling Pathway
|
Table of Contents Download TOC for the report Global Pipeline Review & Analysis of Hematological Malignancies in PDF
|
